CellRep develops an AI-powered platform to discover and validate compounds for non-genetic cell reprogramming. This approach optimizes cellular function to enhance therapeutic potential, addressing limitations in current cell therapies like CAR-T treatments. The company provides an end-to-end pipeline from target discovery through preclinical validation for applications in oncology and longevity.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cell therapies for cancer and chronic conditions often suffer from limited efficacy due to T cell exhaustion and suboptimal functionality. Identifying and validating targets for cell reprogramming remains a bottleneck in developing more potent and durable cell-based treatments.
Solution
CellRep develops cell reprogramming strategies to enhance T cell functionality and improve the efficacy of cell therapies. The company offers an end-to-end pipeline that spans from target discovery to preclinical validation, facilitating the development of more effective cell therapies. By reprogramming T cells to a rejuvenated state, CellRep aims to unlock their full therapeutic potential. Their integrated approach streamlines the process of identifying and validating druggable targets, optimizing drug screening, and conducting preclinical testing.
Target Audience
CellRep's primary customers are cell therapy companies and research institutions focused on developing advanced immunotherapies for cancer and chronic diseases.
Features
- Bioinformatics and AI-driven target discovery for identifying druggable targets.
- Optimized in vitro drug screening platform for single-cell level biomarker analysis.
- Cutting-edge in vivo models for preclinical proof-of-concept studies.
- Cell reprogramming strategies to enhance T cell functionality.
- Integration of cell reprogramming strategies into the cell therapy manufacturing workflow.